Dichlorobenzoprim
Latest Information Update: 23 Jan 2007
Price :
$50 *
At a glance
- Originator Aston University
- Class Antineoplastics
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jan 2007 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Oct 1997 No-Development-Reported for Cancer in United Kingdom (Unknown route)